Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics.
Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.
Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
July 13, 2017
RegMed Investors’ (RMi) closing bell, sector and indexes jockey for altitude
July 12, 2017
RegMed Investors’ (RMi) closing bell, a rising tide
July 12, 2017
RegMed Investors’ (RMi) pre-open indications, will the algorithms like you today …
July 11, 2017
RegMed Investors’ (RMi) closing bell, there are just too many fire drills
July 10, 2017
RegMed Investors’ (RMi) closing bell, the sector stutter steps …
June 30, 2017
RegMed Investors’ (RMi) closing bell, start reversing the “curse”
June 21, 2017
RegMed Investors’ (RMi) closing bell, some substantial gains
May 25, 2017
RegMed Investors’ (RMi) closing bell, sector selling kept coming
May 24, 2017
RegMed Investors’ (RMi) closing bell, which indication is actual performance based?
May 23, 2017
RegMed Investors’ (RMi) closing bell, share pricing as musical chairs
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cesca Therapeutics (KOOL) – January '18 opened at $3.10 and it's beed downhill until February at $2.75 with some upside to $2.95 on 2/16. NOT a believer ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.